3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
pembrolizumab
50
Nivolumab
21
Docetaxel
11
atezolizumab
7
Ipilimumab
7
avelumab
6
Cyclophosphamide
6
Paclitaxel
5
Cetuximab
5
Carboplatin
5
fludarabine
4
Radiotherapy
4
Gemcitabine
4
utomilumab
3
spartalizumab
3
lenvatinib
3
durvalumab
3
Trastuzumab
3
Specimen Handling
3
Interleukin-2
3
Cisplatin
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
tremelimumab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
obinutuzumab
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Genitourinary
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts